 | • レポートコード：TPM-B06014 • 出版社/出版日：Transparency Market Research / 2018年5月30日 • レポート形態：英文、PDF、193ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、サラセミア治療の世界市場について調べ、サラセミア治療の世界規模、市場動向、市場環境、治療タイプ別（輸血、キレート療法、骨髄移植、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・サラセミア治療の世界市場動向 ・サラセミア治療の世界市場環境 ・サラセミア治療の世界市場規模 ・サラセミア治療の世界市場規模：治療タイプ別（輸血、キレート療法、骨髄移植、その他） ・サラセミア治療の世界市場：地域別市場規模・分析 ・サラセミア治療の北米市場規模・予測 ・サラセミア治療のアメリカ市場規模・予測 ・サラセミア治療の中南米市場規模・予測 ・サラセミア治療のヨーロッパ市場規模・予測 ・サラセミア治療のアジア市場規模・予測 ・サラセミア治療の中国市場規模・予測 ・サラセミア治療のインド市場規模・予測 ・サラセミア治療の中東市場規模・予測 ・サラセミア治療のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Thalassemia Treatment Market – Overview
This report analyzes the current and future scenario of the global thalassemia treatment market. Large number of health care investors such as governments, social security funds, and insurance companies are struggling to meet the rising costs of medical treatments and research & development. Promising pipeline drugs and novel therapies, programs for increasing awareness about thalassemia, and rise in prevalence of thalassemia are the major drivers of the global thalassemia treatment market.
The global thalassemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises pipeline of thalassemia treatment by country/region, prevalent treatment regimens by country/region, and cost of treatment by region/country to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global thalassemia treatment market.
Based on treatment type, the global thalassemia treatment market has been segmented into blood transfusion, chelating therapy, bone marrow transplant, others (surgery, general medicines, etc.). These segments have been analyzed based on available approved treatment procedure, cost-effectiveness, and preference for treatment by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Geographically, the global thalassemia treatment market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, ASEAN countries, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global thalassemia treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, Shire plc (Takeda Pharmaceuticals), Incyte Corporation, Kiadis Pharma, Gamida Cell, Bellicum Pharmaceuticals, and GlaxoSmithKline plc.
The global thalassemia treatment market has been segmented as given below:
Global Thalassemia Treatment Market, by Treatment Type
Blood Transfusion
Chelation Therapy
Bone Marrow Transplantation
Others
Global Thalassemia Treatment Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
ASEAN Countries
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Thalassemia Treatment Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Pipeline of Thalassemia Treatment
4.8. Prevalence & Demography – Thalassemia Disease – by Region/Country
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9. Cost of Treatment-By Region/Country
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.9.5. Middle East & Africa
4.10. Prevalent Treatment Regimens – By Country/Region
4.10.1. Asia Pacific
4.10.2. Middle East & Africa
4.11. List of Major Hospitals for Thalassemia Treatment – By Region/ Country/State
4.11.1. North America
4.11.2. Europe
4.11.3. Asia Pacific
4.11.4. Latin America
4.11.5. Middle East & Africa
4.12. Regulatory Scenario, by Region
4.12.1. North America
4.12.2. Europe
4.12.3. Asia Pacific
Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast, by Treatment Type, 2016–2026
5.3.1. Blood Transfusion
5.3.2. Chelation Therapy
5.3.3. Bone Marrow Transplant
5.3.4. Others
5.4. Market Attractiveness, by Treatment Type
Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
6.1. Key Findings
6.2. Market Value Forecast, by Region
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3. Market Attractiveness, by Country/Region
Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.2. Market Value Forecast, by Treatment Type, 2016–2026
7.2.1. Blood Transfusion
7.2.2. Chelation Therapy
7.2.3. Bone Marrow Transplant
7.2.4. Others
7.3. Market Value Forecast, by Country, 2016–2026
7.3.1. U.S.
7.3.2. Canada
7.4. Market Attractiveness Analysis
7.4.1. By Treatment Type
7.4.2. By Country
Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2016–2026
8.2.1. Blood Transfusion
8.2.2. Chelation Therapy
8.2.3. Bone Marrow Transplant
8.2.4. Others
8.3. Market Value Forecast, by Country/Sub-region, 2016–2026
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country/Sub-region
Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2016–2026
9.2.1. Blood Transfusion
9.2.2. Chelation Therapy
9.2.3. Bone Marrow Transplant
9.2.4. Others
9.3. Market Value Forecast, by Country/Sub-region, 2016–2026
9.3.1. China
9.3.2. India
9.3.3. ASEAN countries
9.3.4. Rest of Asia Pacific
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region
Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast, by Treatment Type, 2016–2026
10.2.1. Blood Transfusion
10.2.2. Chelation Therapy
10.2.3. Bone Marrow Transplant
10.2.4. Others
10.3.Market Value Forecast, by Country/Sub-region, 2016–2026
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4.Market Attractiveness Analysis
10.4.1. By Treatment Type
10.4.2. By Country/Sub-region
Chapter 11. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2016–2026
11.2.1. Blood Transfusion
11.2.2. Chelation Therapy
11.2.3. Bone Marrow Transplant
11.2.4. Others
11.3.Market Value Forecast, by Country/Sub-region, 2016–2026
11.3.1. GCC countries
11.3.2. South Africa
11.3.3. Rest of Middle East & Africa
11.4.Market Attractiveness Analysis
11.4.1. By Treatment Type
11.4.2. By Country/Sub-region
Chapter 12. Competition Landscape
12.1.Market Player – Market Presence (2017)
12.1.1. Current Offerings
12.1.2. Strategy
12.2.Company Profiles
12.2.1. bluebird bio, Inc.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. SWOT Analysis
12.2.1.4. Financial Overview
12.2.1.5. Strategic Overview
12.2.2. Acceleron Pharma, Inc.
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. SWOT Analysis
12.2.2.4. Financial Overview
12.2.2.5. Strategic Overview
12.2.3. Novartis AG
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. SWOT Analysis
12.2.3.4. Financial Overview
12.2.3.5. Strategic Overview
12.2.4. Celgene Corporation
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. SWOT Analysis
12.2.4.4. Financial Overview
12.2.4.5. Strategic Overview
12.2.5. Shire Plc. (Takeda Pharmaceuticals)
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. SWOT Analysis
12.2.5.4. Financial Overview
12.2.5.5. Strategic Overview
12.2.6. Incyte Corporation
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. SWOT Analysis
12.2.6.4. Financial Overview
12.2.6.5. Strategic Overview
12.2.7. Kiadis Pharma
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. SWOT Analysis
12.2.7.4. Financial Overview
12.2.7.5. Strategic Overview
12.2.8. Bellicum Pharmaceuticals
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. SWOT Analysis
12.2.8.4. Financial Overview
12.2.8.5. Strategic Overview
12.2.9. GlaxoSmithKline plc
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. SWOT Analysis
12.2.9.4. Financial Overview
12.2.9.5. Strategic Overview
12.2.10. Others
Table 01: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 02: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 03: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 04: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 05: U.S. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 06: Canada Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 07: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 09: U.K. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 10: Germany Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016-2026
Table 11: France Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 12: Italy Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 13: Spain Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 14: Rest of Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 15: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 17: India Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 18: China Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 19: ASEAN Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 20: Rest of Asia Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 21: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 23: Brazil Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 24: Mexico Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 25: Rest of Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 26: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 28: South Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 29: GCC Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 30: Rest of Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026